Postprandial Glucose

Postprandial Glucose

Postprandial glucose is the level of glucose in the blood after you eat, usually measured one or two hours after the start of a meal. In healthy people it rarely goes above 7.8 mmol/L (140 mg/dL), thanks to insulin release, glucose uptake by the liver and glucose clearance by other tissues working together. In people with impaired glucose tolerance or type 2 diabetes, these controls are weakened, so blood sugar rises higher and stays up longer after meals. That adds to the overall blood sugar burden reflected in higher hemoglobin A1c levels.

High blood sugar after meals is increasingly seen as a separate risk factor for cardiovascular disease, even when fasting blood sugar is normal. Post-meal spikes promote oxidative stress, damage to the lining of blood vessels and the formation of advanced glycation end-products, all of which speed up the hardening of the arteries. So treatments that target post-meal blood sugar, including incretin-based drugs, alpha-glucosidase inhibitors and rapid-acting insulins, now play a bigger role in diabetes care. The incretin hormones GLP-1 and GIP are especially good at lowering post-meal glucose, because the body releases them in response to eating.

Clinical Relevance to Retatrutide

Retatrutide tackles post-meal blood sugar rises in several complementary ways. GLP-1 receptor activation boosts glucose-dependent insulin release, curbs unneeded glucagon release from alpha cells and slows gastric emptying so nutrients are absorbed more gradually. GIP receptor activation strengthens the insulin response to meals further. In clinical trials in people with type 2 diabetes, retatrutide significantly reduced post-meal glucose spikes and improved fasting glucose and hemoglobin A1c, consistent with a multi-receptor drug that addresses both the incretin deficit and the wider metabolic problems typical of the disease.